Bright Minds Biosciences Inc Stock Price, News & Analysis

Bright Minds Biosciences (NASDAQ: DRUG) has announced its upcoming virtual R&D Day focusing on Absence Epilepsy, scheduled for May 20, 2025. The event will feature three distinguished Key Opinion Leaders (KOLs) in epilepsy research: - Dr. Dennis Dlugos from Children's Hospital of Philadelphia, an expert in pediatric neurology - Professor Wendyl D'Souza from St Vincent's Hospital, specializing in epilepsy and neurology - Dr. Alexander Rotenberg from Boston Children's Hospital, leading neuromodulation research The R&D Day will highlight the burden of Absence seizures, their long-term patient impact, and the need for novel treatments. The company will discuss their BREAKTHROUGH study, a Phase 2 clinical trial of BMB-101 for Absence Epilepsy and Developmental and Epileptic Encephalopathy (DEE). The virtual event will run from 10:00 am to 11:30 am ET, with a Q&A session included.

Bright Minds Biosciences (NASDAQ: DRUG) has announced positive results from its DBA/2 mouse model study evaluating BMB-101, its novel 5-HT2C Gq-protein biased agonist. The study demonstrated that BMB-101 completely eliminated drop attacks in the DBA/2 mouse model and achieved 100% survival rate by reversing brainstem serotonin deficits and preventing seizure-induced respiratory arrest.

The DBA/2 mouse model is particularly significant as it replicates phenomena such as tonic/clonic seizures, drop attacks, and sudden unexpected death in epilepsy (SUDEP). These findings are crucial as SUDEP is the leading cause of seizure-related premature death, especially in drug-resistant epilepsy patients. For Dravet syndrome patients, the risk of premature death is estimated at 15-20%, with over half attributed to SUDEP.

Bright Minds Biosciences (NASDAQ: DRUG) has announced a virtual R&D Day scheduled for May 20, 2025, from 10:00 am to 11:30 am ET. The event will spotlight the company's focus on absence seizures and their ongoing BREAKTHROUGH study - a Phase 2 clinical trial evaluating BMB-101.

The webcast will feature presentations from Key Opinion Leaders (KOLs) in epilepsy research, examining the unmet needs in epilepsy patients. The BREAKTHROUGH study specifically evaluates the safety, tolerability, and efficacy of BMB-101 in adult patients with classic Absence Epilepsy and Developmental and Epileptic Encephalopathy (DEE).

The R&D Day will be accessible via webcast, with a replay available in the 'Investors' section under 'Events and Presentations' on the company's website.

Bright Minds Biosciences (NASDAQ: DRUG) has expanded its Scientific Advisory Board with five distinguished experts in epilepsy research. The new members include Dennis Dlugos, Jacqueline French, Terrence O'Brien, Jo Sourbron, and Joseph Sullivan, bringing extensive experience in epilepsy drug development and research.

This expansion aligns with the company's clinical focus on developing selective 5-HT2 agonists for treating drug-resistant epilepsy, depression, and CNS disorders. The company is currently conducting a Phase 2 BREAKTHROUGH study of BMB-101 in adult patients with classic Absence Epilepsy and Developmental Epileptic Encephalopathy (DEE).

Additionally, Bright Minds has granted stock options to purchase 161,000 common shares at US$35.00 per share and 600 Restricted Stock Units to directors, officers, and consultants. The options have a four-year term with vesting periods.

Bright Minds Biosciences (NASDAQ: DRUG), a company developing selective 5-HT2 agonists for treating drug-resistant epilepsy, depression, and CNS disorders, has announced its participation in three major healthcare conferences in March 2025.

The company's CEO Ian McDonald and senior management will attend:

• TD Cowen 45th Annual Health Care Conference in Boston on March 3, 2025, at 1:10pm ET
• Leerink Partners Global Healthcare Conference in Miami on March 12, 2025 (one-on-one meetings)
• BIO-Europe Spring in Milan from March 17-19, 2025

Live and archived webcasts will be available on the company's investor relations website for 90 days following the events.

Bright Minds Biosciences (NASDAQ: DRUG) has appointed Stephen D. Collins, M.D., Ph.D., as Chief Medical Officer (CMO), effective immediately. Dr. Collins brings extensive experience in drug development and clinical expertise in epilepsy, replacing Mark A. Smith M.D., Ph.D., who will retire as Acting CMO but continue in an advisory role.

The appointment comes as the company advances its BREAKTHROUGH Study, a Phase 2 clinical trial evaluating BMB-101 in adult patients with classic Absence Epilepsy and Developmental Epileptic Encephalopathy (DEE). Dr. Collins previously served as CEO of Biscayne Neurotherapeutics and Biscayne Pharmaceuticals, which was acquired by Supernus Pharmaceuticals. His track record includes leadership roles at Johnson & Johnson, Abbott Laboratories, and Ovation Pharmaceuticals, where he contributed to the development and approval of multiple anti-convulsant therapies.

Bright Minds Biosciences (NASDAQ: DRUG) announces two presentations at the American Epilepsy Society 2024 Annual Meeting in Los Angeles, December 6-10, 2024. The presentations will showcase data on BMB-101, their novel 5-HT2C agonist.

The first presentation by CSO Jan Torleif Pedersen will discuss Phase I study results on safety, tolerability, and pharmacokinetics of BMB-101. The second presentation by COO Alex Vasilkevich will focus on BMB-101's biased 5-HT2C agonism for epilepsy management. Both poster presentations are scheduled for Saturday, December 7, from 12:00 PM to 2:00 PM at South Hall H, Level 1.

Bright Minds Biosciences (CSE: DRUG) (NASDAQ: DRUG) has successfully closed a non-brokered private placement, raising USD$35 million through the issuance of 1,612,902 common shares at USD$21.70 per share. Notable participants include Cormorant Asset Management, RA Capital Management, Perceptive Advisors, and other healthcare investors. The proceeds will fund research and development programs and general working capital. The offering included insider participation from director Jeremy Fryzuk and Cormorant Asset Management, who collectively subscribed for 188,940 shares worth USD$4.1 million.

Bright Minds Biosciences (NASDAQ: DRUG) has announced a renewed collaboration with Firefly Neuroscience (NASDAQ: AIFF) for the analysis of EEG data from the BREAKTHROUGH study, a Phase 2 clinical trial of BMB-101. This open-label trial is evaluating the safety, tolerability, and efficacy of BMB-101, a selective 5-HT2C receptor agonist, in adult patients with classic Absence Epilepsy and Developmental Epileptic Encephalopathy (DEE).

The study is designed as a basket clinical trial, targeting enrollment of 20 adult participants aged 18-65. It aims to address rare epilepsy disorders characterized by refractory seizures resistant to current treatments. Bright Minds believes BMB-101 has the potential to be a best-in-class 5-HT2C agonist with broad applicability across 30% of epilepsy patients experiencing drug resistance.